Uncategorized – Page 20

OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios

1 month ago talkbio0Tagged AI safety, Aortic Valve Insufficiency, Evaluation, HealthBench, healthcare benchmark, language models, medical AI, open-source dataset, OpenAI, Physicians, realistic medical scenarios, rubrics

OpenAI; HealthBench; AI healthcare benchmark; large language models; medical AI evaluation; physician rubrics; realistic medical scenarios; AI safety; open-source dataset

Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets

1 month ago talkbio0Tagged Appointments, Automobiles, biotech industry, Cell Therapy, CEO, Company Split, Galapagos, spinoff, T business

Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business

UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO

1 month ago talkbio0Tagged Andrew Witty, CEO, financial guidance suspension, Leadership Change, personal reasons, Stephen Hemsley, stock drop, Transition Mutation, UnitedHealth Group

UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop

Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California

1 month ago talkbio0Tagged Broad Institute, Clustered Regularly Interspaced Short Palindromic Repeats, Eukaryotic Cells, Federal Circuit, Gene Modification, Intellectual Property, Legal patent, PTAB, University of California

CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

1 month ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Galapagos Reconsiders Company Split After Market Developments

1 month ago talkbio0Tagged Cell Therapy, Company Split, conditions, Drug Development, Galapagos, Leadership Change, Market, strategic review

Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions

Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout

1 month ago talkbio0Tagged CEO, Clinical Trials, CRO, departure - ActRelationshipType, Fortrea, Labcorp, Leadership Change, public company, Stock Decline

Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company

White House Threatens Most Favored Nation Plan to Lower US Drug Prices, but Many Questions Remain

1 month ago talkbio0Tagged Comparison, Drug Prescriptions, drug price, Favored, global price, Nation, Pharmaceutical Policy, Trump administration, U.S., White House

Most Favored Nation; drug pricing; White House; executive order; prescription drugs; Trump administration; US drug prices; global price comparison; pharmaceutical policy